Full Title
A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial CancerPurpose
Researchers want to know if nab-sirolimus works well against endometrial cancer. The people in this study have endometrial cancer that has spread or came back after treatment.
Nab-sirolimus is a drug called a kinase inhibitor. Kinases are proteins that cancer cells need to survive and grow. By blocking these proteins, nab-sirolimus may help slow or stop the growth of your cancer.
If you join this study, you will get nab-sirolimus plus letrozole. Letrozole is a standard treatment for endometrial cancer. Nab-sirolimus is given intravenously (by vein) and letrozole is taken orally (my mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have endometrial cancer that spread or came back after treatment.
- Have recovered from the serious side effects of prior cancer therapies before getting the study treatment.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information and to see if you can join this study, please call Dr. Angela Green’s office at 646-888-6792.